Sodium Ascorbate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Sodium Ascorbate: From an Unspecified Original Indication to Insomnia
One-Sentence Summary
Sodium ascorbate is a form of vitamin C. In Singapore it is registered in one product, a multivitamin infusion powder, but the approved indication text is not available in the data compiled for this report. The TxGNN model predicts it may be effective for insomnia, but there are currently 0 clinical trials and 0 publications supporting this prediction, so it is a model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (the approved indication text on the Singapore licence is empty) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 94.27% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Sodium ascorbate is the sodium salt of vitamin C, an essential nutrient and antioxidant. It is also a cofactor in collagen synthesis. Its original indication cannot be confirmed from the data compiled for this report.
For insomnia, no established mechanistic link has been identified. Ascorbate is not a known sedative or hypnotic. The high score (94.27%) is a graph-based prediction only, and no trial or publication supports it.
Other predictions ranked highly by the model are also unsupported by clinical evidence. They include osteoarthritis (94.12%), enterocolitis (92.73%) and pseudoachondroplasia (92.17%). Of these, osteoarthritis has the most plausible link, through collagen synthesis and antioxidant effects on cartilage. This remains unverified.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN05209P | SOLUVIT N FOR INFUSION (Fresenius Kabi SSPC) | Injection, powder, for solution | Not stated |
Safety Considerations
Please refer to the package insert for safety information.
No drug–drug interaction records were found for this drug.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for insomnia rests only on the model score. There are no clinical trials or publications, no known mechanistic link, and no safety or indication information from the Singapore label. Evidence level is L5.
To proceed, the following is needed:
- The Singapore package insert (indications, warnings, contraindications), obtained from the HSA website
- Mechanism of action data, for example from DrugBank
- A literature and trial search outside the data compiled here, covering insomnia and the other top predictions, especially osteoarthritis
- Evaluation of route compatibility, since the only registered product is an injectable multivitamin infusion
- A priority review of the other predictions (osteoarthritis, enterocolitis), which may be more biologically plausible than insomnia
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.